PRRT2 and uveal melanoma: Given the improved efficacy achieved with concurrent inhibition of both BRAF and MEK, when compared with BRAF inhibition alone, in melanomas harboring BRAF mutations, we hypothesized that concurrent inhibition of PKC and MEK in uveal melanomas driven by activation of the G alpha signaling pathway may similarly result in improved outcomes.